Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

tion is explained by the considerable increase in operating expenses during the first semester of 2008 and by the significant decrease in revenues recognized during the period as indicated above.

Other results

During the first nine months of 2008, net financial income totaled EUR4.6 million compared to EUR3.7 million in the corresponding period of 2007.

The income tax expense incurred by NicOx during the first nine months of 2008 relates to its subsidiaries and amounted to EUR0.2 million, compared to EUR0.03 million during the same period of 2007.

Net result

For the nine months ended September 30, 2008, the net loss amounted to EUR49.7 million compared to EUR13.7 million for the nine months ended September 30, 2007. As indicated above, this very significant increase in net loss in 2008 is due to the strong increase of research and development expenses associated with naproxcinod and from the considerable decrease in the revenues recognized during this period.

Balance sheet items

The indebtedness incurred by NicOx is mainly short-term operating debt. On September 30, 2008, the Company's current liabilities amounted to EUR23.2 million, including EUR18.1 million in accounts payable to suppliers and external collaborators, EUR1.8 million in accrued compensation for employees, EUR1.6 million in deferred revenues due to payments received under collaboration agreements, EUR1.3 million in corporate taxes payable, EUR0.3 million for other liabilities and EUR0.1 million in current income tax payable.

In the first nine months of 2008, NicOx granted Archimica a loan amounting to EUR6.0 million, fully paid on September 30, 2008, as part of the financial terms of the manufacturing and supply agreement with this company.

On September 30, 2008, the Company's current and non-current financial instruments and cash and cash equivalents were EUR124.8 million, compared to EUR172.8 million on December 31, 2007. The Company us
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... February 2 , Scientists from ... the first variation in the sequence of the human genome ... variant (or SNP),was discovered by analyzing the genomes of a ... Austria, Germany and the United,States. It is located on the ...
... Repligen Corporation (Nasdaq: RGEN ) announced ... Walter C. Herlihy, Ph.D., will present at the BIO ... at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 ... the presentation will be available via Repligen,s website at ...
... (Nasdaq: IPCM ), a leading national physician group practice company, announced today that management is scheduled to ... UBS 2009 Global Healthcare Services ... Adam Singer, M.D., Chairman and CEO, ... Jeff Taylor, President and COO, ...
Cached Biology Technology:deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor 2deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor 3deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor 4Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2IPC The Hospitalist Company, Inc. to Present at UBS 2009 Global Healthcare Services Conference 2
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... had megadroughts more extreme and widespread than any previously known ... now-lush tropical Africa was an arid scrubland during the early ... Africa and the evolution of fishes in Africa,s Great Lakes. ... the world, acts as a rain gauge," said lead scientist ...
... Indiana University environmental science professor and several colleagues suggests ... the potential to harm aquatic ecosystems. The study is ... Proceedings of the National Academies of Sciences . ... in the IU School of Public and Environmental Affairs, ...
... chicken genome or the egg genome? Researchers have answered ... of the thousands of long stretches of repeated DNA in ... The answers, published online by Nature Genetics ... the duplications in the human genome that are partly responsible ...
Cached Biology News:Newfound ancient African megadroughts may have driven the evolution of humans and fishes 2Newfound ancient African megadroughts may have driven the evolution of humans and fishes 3Newfound ancient African megadroughts may have driven the evolution of humans and fishes 4Study shows genetically engineered corn could affect aquatic ecosystems 2Study shows genetically engineered corn could affect aquatic ecosystems 3Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... In virtually every research laboratory, the ... of information accurately, inexpensively and in real ... compact lab analysis system includes the Luminex ... It utilizes xMAP technology which enables you ...
... Analysis of large numbers of samples may ... gradient system, which requires minimum operator attention. ... by PowerStream software and interface CE 4900. ... software operates in Windows XP and Windows 98 ...
Biology Products: